Abstract：
This study compared the efficacy of modified CO2 laser-assisted sclerectomy surgery (CLASS) with combined CLASS and trabeculectomy (CLASS-TRAB) in patients with uveitic glaucoma (UG). UG patients who underwent CLASS-TRAB between August 2015 and April 2019 were retrospectively compared with a control group who underwent a modified CLASS standalone procedure during the same period. Visual acuity, intraocular pressure (IOP), use of supplemental medical therapy and postoperative complications were recorded at baseline, 1 week, 3 months, 6 months and 12 months. Forty patients (40 eyes) were enrolled, and each group had 20 patients (20 eyes). The age and sex distribution were matched between groups (P > 0.05). Both the preoperative IOP (CLASS: 34.9 ± 9.3 mmHg, CLASS-TRAB: 36.8 ± 8.7 mmHg; P > 0.05) and number of glaucoma medications (CLASS: 3.3 ± 0.4, CLASS-TRAB: 3.5 ± 0.5; P > 0.05) were relatively higher in the CLASS-TRAB group than in the CLASS group. At the final follow-up, the IOP (CLASS: 12.9 ± 3.4 mmHg, CLASS-TRAB: 11.2 ± 2.5 mmHg) and number of glaucoma medications (CLASS: 0.4 ± 0.7 and CLASS-TRAB: 0.2 ± 0.5) significantly decreased in both groups (P < 0.01). Both the complete success rate and qualified success rate were comparable between the two groups (CLASS versus CLASS-TRAB: 55% versus 80%, P = 0.09; 80% versus 95%, P = 0.34). CLASS-TRAB is as efficient as modified CLASS in terms of the IOP-lowering effect, providing a new option for patients with UG that is severe and ineligible for other treatments.
摘要：
这项研究比较了改良CO2激光辅助巩膜切除术（CLASS）与CLASS和小梁切除术（CLASS-TRAB）联合治疗葡萄膜青光眼（UG）的疗效。在2015年8月至2019年4月期间接受CLASS-TRAB的UG患者与同期接受改良CLASS独立手术的对照组进行回顾性比较。视敏度,眼内压（IOP），基线时记录补充药物治疗的使用和术后并发症,1周,3个月,6个月和12个月。纳入40例患者（40只眼），每组20例(20只眼)。组间年龄、性别分布比较差异无统计学意义(P>0.05)。术前眼压（CLASS：34.9±9.3mmHg，CLASS-TRAB组：36.8±8.7mmHg；P>0.05）和青光眼药物数量（CLASS：3.3±0.4，CLASS-TRAB：3.5±0.5；P>0.05）相对高于CLASS组。在最后的后续行动中，眼压（等级：12.9±3.4mmHg，CLASS-TRAB：11.2±2.5mmHg）和青光眼药物数量（CLASS：0.4±0.7和CLASS-TRAB：0.2±0.5）两组均显着减少（P<0.01）。两组之间的完全成功率和合格成功率具有可比性（CLASS与CLASS-TRAB：55％与80％，P=0.09；80%对95%，P=0.34）。CLASS-TRAB在降低IOP的作用方面与改良CLASS一样有效，为严重且不适合其他治疗的UG患者提供新的选择。
